Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-MESO CAR-T in Refractory-Relapsed Ovarian Cancer
NCT03814447Phase 1Unknown
- Sponsor
- Shanghai Sixth People's Hospital
- Start
- Aug 2019
- Primary completion
- Jan 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-mesothelin CAR-T cells in ovarian cancer, sponsored by Shanghai Sixth People's Hospital. Primary endpoint: Adverse events and Serious adverse events. Status: unknown.
02
Drugs
anti-mesothelin CAR-T cells
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03814447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03814447.